Exit edit profile

Edit your staff profile

Your staff profile is made up of information taken from systems including Pure and Subscribe.  This page explains how to update each section of your profile.

Dr Matthew Blunt

 PhD
Associate Professor

Accepting applications from PhD students.

Connect with Matthew

Email: M.D.Blunt@soton.ac.uk

Tel: +44 2381206671

Google Scholar
ORCID
LinkedIn

Profile photo 
Upload your profile photo in Subscribe (opens in a new tab). Your profile photo in Pure is not linked to your public staff profile. Choose a clear, recent headshot where you are easily recognisable. Your image should be at least 340 by 395 pixels. 

Name 
To change your name or prefix title contact Ask HR (opens in new tab)  If you want to update an academic title you'll need to provide evidence e.g. a PhD certificate. The way your name is displayed is automatic and cannot be changed. You can also update your post-nominal letters in Subscribe (opens in a new tab).

Job title 
Raise a request through ServiceNow (opens in a new tab) to change your job title (40 characters maximum) unless you're on the ERE career pathway. If you're on the ERE path you can not change your main job title, but you can request other minor updates through Ask HR (opens in new tab). If you have more than one post only your main job title will display here, but you can add further posts or roles in other sections of your profile.

Research interests (for researchers only) 
Add up to 5 research interests. The first 3 will appear in your staff profile next to your name. The full list will appear on your research page. Keep these brief and focus on the keywords people may use when searching for your work. Use a different line for each one.

In Pure (opens in a new tab), select ‘Edit profile’. Under the heading 'Curriculum and research description', select 'Add profile information'. In the dropdown menu, select 'Research interests: use separate lines'.

Contact details 
Add or update your email address, telephone number and postal address in Subscribe (opens in a new tab). Use your University email address for your primary email. 

You can link to your Google Scholar, LinkedIn and Twitter accounts through Pure (opens in a new tab). Select ‘Edit profile’.  In the 'Links' section, use the 'Add link' button. 

ORCID ID 
Create or connect your ORCID ID in Pure (opens in a new tab). Select ‘Edit profile’ and then 'Create or Connect your ORCID ID'.

Accepting PhD applicants (for researchers only) 
Choose to show whether you’re currently accepting PhD applicants or not in Pure (opens in a new tab). Select ‘Edit profile’. In the 'Portal details' section, select 'Yes' or 'No' to indicate your choice. 

About Research Publications Supervision Teaching External roles and responsibilities Biography
Exit edit profile

About

Dr Matthew Blunt leads a research team focused on natural killer (NK) cells and the utilisation of immune cells to provide safer and more effective treatments for people with cancer. His research group interacts closely with clinicians at the University Hospital Southampton and with collaborators from both academia and the pharmaceutical industry.

 

Examples of published research include:

 

  • The nuclear export protein XPO1 provides a peptide ligand for natural killer cells (Blunt MD et al, Science Advances, 2024)

 

  • Lymph node associated signals inhibit NK activation against leukemic cells via the immune checkpoint NKG2A (Fisher JG...Blunt MD, Leukemia, 2023)

 

  • KIR2DS2 expression identifies NK cells with enhanced anti-cancer activity (Blunt MD et al, Journal of Immunology, 2022)

 

  • XPO1 inhibition stimulates NK cell activation against lymphoma cells (Fisher JG...Blunt MD, Frontiers in Oncology, 2021).

 

  • Development of a novel therapeutic to activate NK cells against cancer (Rettman P, Blunt MD et al, Journal for immunotherapy of cancer, 2021).

 

  • Targeting the PI3K/mTOR pathway in leukaemia (Blunt MD et al, Blood, 2015).

 

  • Identification of IL-4 as a resistance mechanism to idelalisib and ibrutinib in leukaemia (Aguilar-Hernandez M, Blunt MD et al, Blood, 2016 *Co-first author).

 

  • Preclinical evaluation of the dual SYK/JAK inhibitor cerdulatinib alone and in combination with venetoclax in leukaemia (Blunt MD et al, Clinical Cancer Research, 2016).

You can update this in Pure (opens in a new tab). Select ‘Edit profile’. Under the heading and then ‘Curriculum and research description’, select ‘Add profile information’. In the dropdown menu, select - ‘About’.

Write about yourself in the third person. Aim for 100 to 150 words covering the main points about who you are and what you currently do. Clear, simple language is best. You can include specialist or technical terms.

You’ll be able to add details about your research, publications, career and academic history to other sections of your staff profile.

Update this section in Pure